Ashland Inc. (ASH) recorded fourth-quarter fiscal 2024 (ended Sept. 30, 2024) adjusted earnings of $1.26 per share, up from 41 cents in the prior-year quarter. The bottom line lagged the Zacks Consensus Estimate of $1.33.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Sales for the reported quarter were up around 1% year over year to $522 million. It beat the Zacks Consensus Estimate of $518.7 million. ASH saw higher sales volumes in Personal Care, Specialty Additives and Intermediate ...

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of a new facility financing the acquisition of a Boeing 737-800 for Crestone Air Partners, Inc. ("Crestone"), Air T, Inc. ("Air T") and Mill Road Capital Management LLC ("Mill Road").This is the third transaction that the Ashland Place platform has completed with Crestone, having previously financed the acquisitions of three Boeing 737-800 freighters i ...

Ashland Inc. (NYSE:ASH) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operato ...

earnings conference call fourth quarter fiscal 2024 — November 7, 2024 9:00 a.m. ET 2 — Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," " ...

WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland’s strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025. The event will include presentations and prepared remarks from members of Ashland’s executive team, as well as breakout ses ...

Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study Highlights Company’s Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom’s Macroglobulinemia FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today annou ...

For the quarter ended September 2024, Ashland (ASH) reported revenue of $522 million, up 0.8% over the same period last year. EPS came in at $1.26, compared to $0.41 in the year-ago quarter.The reported revenue represents a surprise of +0.63% over the Zacks Consensus Estimate of $518.74 million. With the consensus EPS estimate being $1.33, the EPS surprise was -5.26%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this chemical company would post earnings of $1.47 per share when it actually produced earnings of $1.49, delivering a surprise of 1.36%.Over the last four quarters, the company h ...

Exhibit 99.1 Ashland reports financial results for fourth-quarter fiscal 20241, issues outlook for full-year fiscal 2025, provides portfolio optimization update and announces strategy update event Financial results for fourth-quarter fiscal 2024 1 • Sales of $522 million, up one percent from the prior-year quarter • Sold nutraceuticals business to Turnspire Capital Partners LLC • Previously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives red ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company's key drug candidate, lisaftoclax (APG-2575), have been selected for presentations, including an Oral Report, at the 66th American Society of Hematology (ASH) Annua ...